Pharma’s $106 Billion Summer: The Bolt-On Strategy to Beat the Patent Cliff
How a surge in targeted mid-sized acquisitions is reshaping oncology and metabolic pipelines as major drugmakers brace for a revenue…
Decoding the Science of Life
Decoding the Science of Life
How a surge in targeted mid-sized acquisitions is reshaping oncology and metabolic pipelines as major drugmakers brace for a revenue…